RVMD (STOCKS)
Revolution Medicines, Inc. Common Stock
$159.698100
+5.828100 (+3.79%)
Prev close: $153.870000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Other
- CEO
- Mark A. Goldsmith
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $34,023.94M
- Employees
- 809
- P/E (TTM)
- -22.63
- P/B (TTM)
- 20.54
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
11
Strong Buy
15
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-2.29 | $-1.88 | -0.4140 | -22.07% |
|
Dec 2025 (Q4)
|
$-1.86 | $-1.61 | -0.2477 | -15.36% |
|
Sep 2025 (Q3)
|
$-1.61 | $-1.45 | -0.1627 | -11.24% |
|
Jun 2025 (Q2)
|
$-1.31 | $-1.16 | -0.1486 | -12.79% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $15.13M |
| Operating Expenses | $1.39B |
| Research and Development | $1.13B |
| Other Operating Expenses | $261.28M |
| Operating Income/Loss | -$1.39B |
| Income/Loss From Continuing Operations After Tax | -$1.37B |
| Income/Loss From Continuing Operations Before Tax | -$1.37B |
| Net Income/Loss | -$1.37B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$1.37B |
| Net Income/Loss Available To Common Stockholders, Basic | -$1.37B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$7.10 |
| Diluted Earnings Per Share | -$7.10 |
| Basic Average Shares | 577,384,491 |
| Diluted Average Shares | 577,384,491 |
| Assets | $2.25B |
| Current Assets | $1.97B |
| Noncurrent Assets | $285.82M |
| Fixed Assets | $31.48M |
| Intangible Assets | $55.80M |
| Other Non-current Assets | $198.55M |
| Liabilities | $753.82M |
| Current Liabilities | $289.60M |
| Accounts Payable | $80.54M |
| Other Current Liabilities | $209.06M |
| Noncurrent Liabilities | $464.22M |
| Equity | $1.50B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.50B |
| Liabilities And Equity | $2.25B |
| Net Cash Flow From Operating Activities | -$1.06B |
| Net Cash Flow From Operating Activities, Continuing | -$1.06B |
| Net Cash Flow From Investing Activities | $306.62M |
| Net Cash Flow From Investing Activities, Continuing | $306.62M |
| Net Cash Flow From Financing Activities | $859.39M |
| Net Cash Flow From Financing Activities, Continuing | $859.39M |
| Net Cash Flow | $108.55M |
| Net Cash Flow, Continuing | $108.55M |
| Comprehensive Income/Loss | -$1.37B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$1.37B |
| Other Comprehensive Income/Loss | -$307.12M |